Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.81
    +0.24 (+0.29%)
     

  • Bitcoin CAD

    87,878.59
    +87.80 (+0.10%)
     

  • CMC Crypto 200

    1,390.17
    +7.60 (+0.55%)
     

  • GOLD FUTURES

    2,344.90
    +2.40 (+0.10%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,767.00
    +199.50 (+1.14%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,934.91
    +306.43 (+0.81%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Today’s Research Reports on Stocks to Watch: Nektar Therapeutics and Zosano Pharma

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / March 5, 2018 / Shares of Nektar Therapeutics and Zosano Pharma both blew up in Friday trading. Nektar saw big gains after reporting better than expected fourth quarter results and Zosano leaped ahead after announcing a U.S. patent covering M207, an acute treatment for migraines.

RDI Initiates Coverage on:

Nektar Therapeutics
https://rdinvesting.com/report/?ticker=NKTR

Zosano Pharma Corporation
https://rdinvesting.com/report/?ticker=ZSAN

Nektar Therapeutics shares closed up 21.67% on nearly 6.6 million shares traded on Friday. The stock soared to a new high of $104.93 during intra-day trading after the biotech firm reported stellar quarterly results. For the fourth quarter the company posted revenue of $99.5 million. Even if the non-recurring revenue of $60 million is excluded, it still exceeds the $31.5 million expected by analysts. In the year ago quarter Nektar had posted $37.5 million. Traders were extremely enthusiastic over the result. CEO Howard W. Robin remarked, "This past year was truly transformational for Nektar as we achieved a number of successes with Nektar medicines across our three key therapeutic areas of immuno-oncology, immunology and pain." The company has also signed a partnership with Bristol-Myers Squibb that provided an upfront payment of $1.85 billion. Bristol paid this sum to grab 35% of the potential opportunity that NKTR-214 may have as a hopeful treatment for multiple-solid tumor cancers. Since the year began, shares of Nektar are up over 72%.

ADVERTISEMENT

Access RDI's Nektar Therapeutics Research Report at:
https://rdinvesting.com/report/?ticker=NKTR

Zosano Pharma Corporation shares exploded on Friday closing the day up 39.38% on high trading volume compared to usual. The clinical stage biopharma company announced on Friday the issuance of a new U.S. patent covering M207 as an acute treatment for migraines. M207 is designed to provide pain relief in the acute treatment of migraine with and without aura in as early as 20 minutes. Last February the company reported positive pivotal data from its Zotrip Phase 2/3 trial. Subjects had been treated with the 3.8mg dose of M207 achieved statistical significance on the co-primary endpoints. It achieved pain freedom and most bothersome symptom freedom at 2 hours. Chairman and Chief Executive Officer, John Walker, remarked, "We are pleased to have this important expansion of our patent estate for M207. This issuance supports our intellectual property strategy for our ADAM technology, and specifically M207. We intend to pursue similar patent coverage for future products that Zosano develops internally, and in future partnerships.”

Access RDI's Zosano Pharma Corporation Research Report at:
https://rdinvesting.com/report/?ticker=ZSAN

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and Zosano Pharma Corporation (NASDAQ: ZSAN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com